Scholarlink

Background <p>This study aimed to investigate the clinical prognostic factors of oral and maxillofacial Langerhans cell histiocytosis (LCH-OMF) and the dynamics of regulatory T (Treg) cells and M2 macrophages.</p> Methods <p>We retrospectively analysed nine patients who were definitively diagnosed with LCH-OMF and examined clinical factors including age, sex, disease type, lesion site, clinical findings, the presence or absence of central nervous system (CNS) risk lesions, other organ lesions, treatment methods and prognosis. Immunohistochemical and fluorescent immunohistochemical analyses were performed to investigate prognostic factors from a cell biological perspective regarding the mechanism of onset in these patients.</p> Results <p>None of the nine patients followed the previously reported clinical prognostic patterns, and no patient with lesions in cranio-maxillofacial bones within the CNS risk region developed CNS-related disease. One patient had multi-system LCH with risk organ involvement (MS [RO +]) and the poorest prognosis; in this case, an increase in Tregs in the LCH lesion may have caused tumour immunosuppression, suggesting an association with disease severity. Findings from this patient suggested that interleukin (IL)-10 secretion by M2 macrophages may be an initiating factor in the mechanisms that regulate tumour growth; however, this interpretation is hypothesis-generating and based on a small number of cases.</p> Conclusion <p>Assessing the prognosis of LCH-OMF requires a comprehensive consideration of the disease type, age, CNS-risk regions, risk organs, acute systemic inflammatory response, and skin involvement. A better understanding of IL-10 derived from Tregs and M2 macrophages in LCH-OMF and in LCH overall may enhance our comprehension of inflammatory dysregulation and Langerhans cell progression in LCH and could help to identify potential treatment strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostic factor analysis of oral and maxillofacial Langerhans cell histiocytosis based on clinical findings and tumour microenvironment

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月10日

查看全文
  • Masaru Ogawa,
  • Satoshi Yokoo,
  • Emi Saitou,
  • Mai Seki,
  • Takahiro Yamaguchi,
  • Keisuke Suzuki,
  • Hideharu Nakamura,
  • Takaya Makiguchi

摘要

Background

This study aimed to investigate the clinical prognostic factors of oral and maxillofacial Langerhans cell histiocytosis (LCH-OMF) and the dynamics of regulatory T (Treg) cells and M2 macrophages.

Methods

We retrospectively analysed nine patients who were definitively diagnosed with LCH-OMF and examined clinical factors including age, sex, disease type, lesion site, clinical findings, the presence or absence of central nervous system (CNS) risk lesions, other organ lesions, treatment methods and prognosis. Immunohistochemical and fluorescent immunohistochemical analyses were performed to investigate prognostic factors from a cell biological perspective regarding the mechanism of onset in these patients.

Results

None of the nine patients followed the previously reported clinical prognostic patterns, and no patient with lesions in cranio-maxillofacial bones within the CNS risk region developed CNS-related disease. One patient had multi-system LCH with risk organ involvement (MS [RO +]) and the poorest prognosis; in this case, an increase in Tregs in the LCH lesion may have caused tumour immunosuppression, suggesting an association with disease severity. Findings from this patient suggested that interleukin (IL)-10 secretion by M2 macrophages may be an initiating factor in the mechanisms that regulate tumour growth; however, this interpretation is hypothesis-generating and based on a small number of cases.

Conclusion

Assessing the prognosis of LCH-OMF requires a comprehensive consideration of the disease type, age, CNS-risk regions, risk organs, acute systemic inflammatory response, and skin involvement. A better understanding of IL-10 derived from Tregs and M2 macrophages in LCH-OMF and in LCH overall may enhance our comprehension of inflammatory dysregulation and Langerhans cell progression in LCH and could help to identify potential treatment strategies.